Apply to trial NCT07043608

A few quick questions so the study team can decide if you might be a fit.

RecruitingPhase 2Drug trial

Zanzalintinib for Metastatic Clear Cell Renal Cell Carcinoma With Bone Metastases

This is a single-institution, phase 2 trial of zanzalintinib plus investigator-choice bone-strengthening agent in patients with metastatic renal cell carcinoma (RCC) with bone metastases whose disease has advanced on 1-3 prior lines of therapy, including at least one immune oncology-based (IO) therapy in the adjuvant or first-line metastatic setting.

How this works

Answer a few questions
About 5 to 10 minutes. Skip-friendly where possible.
We connect you with the study team
When a site picks up your application, we introduce you to their team directly — with you on the thread.
The team reaches out to schedule screening
Usually within a few business days, via the contact you give.

EmailWe save your progress under this email and copy you when we connect you with the study team.

I agree that Hipa.ai may share my application — my name, contact details, and my answers, including health information — with the official study team for this trial so they can review my responses and contact me.

By continuing, you agree to our terms of service.

Zanzalintinib for Metastatic Clear Cell Renal Cell Carcinoma With Bone Metastases

How this works

Answer a few questions

We connect you with the study team

The team reaches out to schedule screening